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Abstract
Background: The Medicines Transparency Alliance (MeTA) is an initiative that brings together all stakeholders in
the medicines market to create a multi-stakeholder dialogue and improve access, availability and affordability of
medicines. Key to this multi-stakeholder dialogue is the participation of Civil Society Organisations. A recent MeTA
annual review, identified uneven engagement of civil society organisations in the multi-stakeholder process. This
study was designed to explore the engagement of Civil Society Organisations in the MeTA multi-stakeholder
process and the factors influencing their participation.
Methods: Participants were drawn from a convenience sample of key MeTA informants attending a MeTA global
meeting in Geneva in 2014. Study participants consisted of members of MeTA, which included representatives from
government, the private sector and civil society. In-depth semi-structured face-to-face interviews were conducted to
identify perceptions around the barriers to civil society engagement in the multi-stakeholder process. Interviews were
guided by a conceptual framework exploring the three main themes of the political environment, relative stakeholder
strength and agenda setting/gatekeepers. Interviews were structured to enable additional themes to emerge and be
explored. Fifteen interviews were conducted. The interviews were audio recorded, transcribed verbatim and analysed
using a general inductive approach. All interviewees provided written informed consent.
Results: Findings were captured within three main overarching themes: the political environment, relative stakeholder
strength and agenda setting/gatekeepers, with the opportunity for additional themes to emerge in the interviewing
process. The study conformed these three themes were important in the engagement process. Participants reported
that civil society engagement is particularly limited by those who set the agenda. It was largely seen that the political
environment was the significant factor that enabled or disabled all others. The findings counter the argument that CSO
barriers to engagement are predominantly due to capacity issues.
Conclusions: This study enriches previous findings by providing insights into civil society participation in
multi-stakeholder dialogue, specifically the MeTA initiative. The development of more rigorous and systematic
accountability mechanisms in order to maintain the legitimacy of decision-making processes and establish
more equal power relations would significantly benefit the engagement of civil society organisations. The
results inform practical recommendations for MeTA and future multi-stakeholder programmes tasked with
improving policy on the access, availability and affordability of medicines.
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Background
Globally, one in three people lacks access to essential med-
icines [1]. Moreover, when access does exist, medicines can
be too expensive, counterfeit or sub-standard, wrongly pre-
scribed or out of stock in the nearest health centre. The
pharmaceutical market and medicine supply chains are at
the root of these problems; poor information on price and
quality, promotion of medicines, distorted competition,
corrupt practices and irrational use of medicines [2]. Un-
derstanding information about the medical supply chain
within health systems is essential to identify how problems
should be tackled and by whom. The Medicines Transpar-
ency Alliance (MeTA) was established in 2008 as a re-
sponse to this. MeTA is premised on the idea that making
information about medicine supply chains available for
analysis by major stakeholder groups will lead to an im-
proved understanding of the problems. This in turn will
foster a greater incentive to pioneer change, greater re-
sponsibility and accountability upon those needed to insti-
gate change and will lead to increased access to medicines
for the most vulnerable sectors of society. In order to
achieve its overall goal, MeTA pursued three key objec-
tives; to better inform pharmaceutical policies, to improve
practice and to enable multi-stakeholder participation [3].
MeTA sought to improve the access, availability and af-
fordability of medicines for seven countries where access is
currently limited (Ghana, Jordan, Kyrgyzstan, Peru, the
Philippines, Uganda and Zambia).
At the country level MeTA was developed in response to
respective political and social contexts. Whilst being a
global alliance, countries were encouraged to shape their
structures, priorities and work programmes within existing
frameworks to ensure the project would be country led
and as sustainable as possible. Each of the pilot countries
has organised a Multi-stakeholder Forum, a Council and a
Secretariat. One of the most fundamental elements of
MeTA in each pilot country was the creation of the
national MeTA Councils as multi-stakeholder groups. It
was vital that governments, the private sector and civil so-
ciety organisations (CSOs) were actively engaged as stake-
holders in each MeTA council. This created an ‘issue
network’; “a relatively open network of antagonistic actors”,
with a mutual aim, who have expert knowledge and build
relationships through information exchange but may sub-
sequently have very different policy ideals [4–8].
The combination of transparency and multi-
stakeholder groups may have been used before [9], but
applying this model to the area of medicines and health
policy was a unique strategy. Indeed, transparency
around medicines policy is not a new concept, MeTA’s
aim was to creating a multi stakeholder alliance, to gen-
erate evidence and translate evidence into policy and
practice [10]. Crucially, for CSOs participating in MeTA
they were being invited to engage in an area where they
had previously found themselves on the margins. Indeed,
the involvement of CSOs in policy decision making in
general is often limited [10]. The CSOs participating in
MeTA consist of community, patient, health, consumer,
good governance and transparency groups, media, and
faith-based organisations - a network of stakeholders
acting in the space between individuals, the state and
the private sector. It is, generally accepted that an engaged
civil society is central to true democratic legitimacy and
promoting accountability [11–14]. Civil Society Organisa-
tions (CSOs) have a long history of involvement on health
and access to essential medicines, consumer protection
and promotion of transparency, including many national
as well as international groups. In-country CSOs are fo-
cused on health in different ways – as service providers,
advocates for rights, or providers of care and support for
people with specific health problems. The inclusion of
CSOs as one of the three stakeholder groupings in the
MeTA pilot was therefore entirely appropriate. However, in
a recent MeTA annual report, despite highlighting the con-
siderable advances MeTA has made since the initial pilot
phase, reports of obstacles preventing full engagement be-
tween CSOs and other stakeholders, were described [15].
To date, little research has been done to explore the full
range of factors that cause variation in the ability of CSOs
to engage meaningfully in policy development or multi-
stakeholder platforms. In the literature, causes of the
unequal engagement of civil society are positioned as
largely stemming from within civil society as opposed to
external factors. Indeed, the most cited factor in determin-
ing civil society engagement is the availability of technical
capacity [16, 17]. However, for MeTA the barriers to CSO
engagement were not perceived as issues arising primarily
from poor technical capacity. The issues appeared to be
more driven by the domestic, social and political context.
Few scholars have tackled the question of what accounts
for the variation in civil society engagement beyond
capacity issues. Explanations are likely to be insufficient if
they do not engage with the reality of the multi-
stakeholder process and the dynamics which push and
pull decisions and issues both inside and outside of CSOs
in different directions. This ‘push and pull’ can be concep-
tualised as issue emergence and the twin steps of the
construction and acceptance of problems as issues. The
construction of issues, which consists of definition and
framing of a problem, is a key part of issue networks and
are logically prior to decisions on issues and solutions
championed by networks. This process demonstrates that
a stakeholder is responsible for a particular issue and issue
acceptance occurs when the issue is championed by at
least one major player in the wider network [18, 19]. How-
ever, where some actors have more power over decision-
making than others, it is likely that CSO perspectives fade
into the background if they contradict the policy plans of
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these gatekeepers. Equally, where the political environ-
ment does not welcome the inclusion of civil society opin-
ions (e.g. where engagement is sporadic or where
government officials have their own agendas) the likeli-
hood of issue acceptance is threatened. In the case of
MeTA, issue acceptance occurs at the internal level of
MeTA and at the level of MeTA-government relations.
Despite the limited literature, a number of questions are
raised which recognise the influence of factors external to
CSOs, such as a highly political policy environment, fear
of political opposition and government suspicion [20–22].
Indeed, this resonates with views from a recent CSO
meeting, where, “relative stakeholder strength, local
cultural issues (e.g. history of democratic process) and
agenda setting/threats” were seen as the key barriers to
CSO engagement [15]. In order to explore this issue in
more depth this study interviewed MeTA members about
their knowledge and experiences of engaging in policy de-
velopment and multi-stakeholder platforms. Exploring the
barriers to CSO participation in MeTA will not only aid in
understanding how the policy dialogue can be improved
around medicines policy but it will also contribute to the




This study adopted a qualitative approach and was
undertaken at the MeTA Global Meeting in November
2014 in Geneva, Switzerland. A list of attendees at the
MeTA Global Meeting was obtained prior to the meet-
ing. Participants for the study were sampled purposively
based on the following criteria: interviewees must be
part of the MeTA alliance (representatives of one of the
three stakeholder groups from the participating coun-
tries of the alliance), must regularly attend meetings and
must speak English or have a translator available. Based
on this selection criterion, fifteen participants were re-
cruited for the study and were sent information regard-
ing the study. This included a participant information
sheet, which provided an overview of the research study
and processes and a research consent form that partici-
pants could complete to indicate their interest in partici-
pating. This information was also passed on by the
researcher conducting the interviews directly prior to
the interview itself. Participants were advised that they
could withdraw from the study at any time.
Interviews
A series of face-to-face, semi-structured interviews was
undertaken. To ensure consistency, interviews were con-
ducted by the same interviewer. Questions were devel-
oped following a review of the relevant literature [1–19]
and by identifying suggested key barriers to civil society
engagement in the 2014 MeTA annual review. These ques-
tions informed a conceptual framework developed to as-
certain what actors perceived as barriers to civil society
engagement. The conceptual framework focused questions
on three main themes: (1) local political environment (2)
power imbalances and (3) agenda setting/gatekeepers.
Additional questions were used to obtain information
about civil society representative’s experiences of multi-
stakeholder engagement and their perception of the ways
in which they were encouraged or discouraged to voice
their opinions. In all interviews, questions were asked
about the power relationships between stakeholders within
and outside of MeTA and factors which facilitated or
inhibited civil society influence on policy change.
Questions were asked in English (using a translator where
necessary) and were open-ended in order to allow discus-
sions to be led by interviewees as opposed to the inter-
viewer. Demographic information, including sector and
country of employment were recorded at the time of the
interview. Interviews took place at a quiet location close by
to the Global Meeting. Fifteen interviews were conducted,
at which stage data saturation was reached. Most inter-
views were around 50 min in duration (range: 20–50 min).
Face to face semi-structured interviews were chosen over
qualitative methods due the opportunity to take advantage
of social ques and allow for additional themes to emerge.
Synchronous communication also gives the advantage of
spontaneous answers and direct reaction on answers. All
participants were interviewed in the same location to
provide a private space for people to partake honestly to
enhance the validity of the study.
Data analysis
After each interview, the interviewer made field notes
and this information was used to describe how each
interview was conducted and to note issues or com-
ments not sufficiently captured by audio recordings.
This information aided interpretation of data. All inter-
views were audiotaped with the consent of participants.
Interviews were transcribed verbatim and the transcripts
were checked against the audio recordings. The full
transcripts used in the subsequent analysis process. To
ensure anonymity, names, place of work, or any other
identifying information was removed, and a unique code
number was assigned to each transcript. Analysis of data
was undertaken by the research team via a staged
process to ensure reliability. In the first instance, tran-
scripts were read after each interview to inform further
interview questions in order to enable continuous com-
parison of new and previous interview content. The
data were analysed using the general inductive ap-
proach (GIA) [21] using the thematic framework as a
guide. GIA is a thematic analysis approach with both
deductive and inductive features. In GIA, while the
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general (or overarching) themes are derived from the
research objectives (deductive feature), more specific
categories/themes arise from the data (inductive feature)
[21]. NVivo 10 software (QSR International) was used to
support the analysis process. Identification and interpret-
ation of quotes was carried out by two separate members
of the research team.
Results
Of the 15 individuals who participated, four were MeTA
country co-ordinators (with civil society backgrounds),
two were representatives of the private sector and the
remaining nine MeTA members were representatives
from civil society. Participants selected represented the
following countries; Jordan, Peru, Kyrgyzstan, Zambia,
Uganda, Philippines, Ghana. Key findings from the re-
search are presented below.
The political environment as a barrier to CSO
engagement
Despite advances in political freedoms, some MeTA
groups operate in political contexts which constrain
civil society work and engagement in policy processes.
The majority of respondents spoke of the importance
of the wider political context to civil society’s ease or
difficulty engaging policy. A history of civil society en-
gagement with government in a democratic setting was
seen as a clear advantage by all respondents, whereas a
lack of this was thought to correspond with difficulties
in civil society participation:
The lack or presence of political will has the power to
disable or enable our [civil society’s] ability to act and
political will has been seriously lacking in Peru…there
is no real history of dialogue between our government
and civil society and the government do not want to
listen to different perspectives. [P3]
Regular consultations between civil society and the
state were seen as a significant advantage to engagement
to civil society representatives in all countries. However,
in some countries, consultations with the ministry of
health were reported to largely take the form of the
provision of evidence for policy change as opposed to
providing insight on policy issues. Some actors expressed
doubts as to what meaningful action could arise from
these consultations. Similarly, the ‘good will’ demonstrated
by allowing civil society to participate in consultative
stages of the policy process was reported to not translate
into further policy action, leaving civil society representa-
tives feeling marginalized:
Sometimes, it feels like our participation inside and
outside of MeTA is just tokenism…we talk and talk
and talk but whether anything materializes…well, let’s
see. [P2]
A civil society representative from Peru explained
that, while it was originally intended for civil society
to provide the government with opinions and recom-
mendations, civil society consultations have been
blocked by ministers:
“…so in the access to essential medicines programme
called Farmacise, civil society are supposed to provide
the government with opinions…recommendations. But
the government has blocked that. They don’t want to
listen to them specifically in that area. It has been
closed for civil society participation so far. That is the
big concern in Peru right now.” [P1]
Unpredictable government engagement with MeTA
was also highlighted as a barrier to civil society en-
gagement, as securing government representatives’
presence and input was seen as integral to getting
MeTA perspectives represented in policy:
In Ghana, we had a challenge with the secretariat.
That’s finished now. There was a secretariat that was
not performing. There today, not there tomorrow. The
new one is better, he gives time. [P9]
In some cases, government officials perceived the pres-
ence or voices of CSOs as diminishing or undermining
the authority of the state. Perceived former civil society
‘interference’ in policy was also seen as a source of tension
by a civil society representative from Ghana, who believed
that this had led to government officials being less recep-
tive to civil society opinions. In Kyrgyzstan, civil society
has an excellent relationship with the ministry of health
but there are tensions between civil society and the De-
partment on Drug Provision and Medical Equipment in
the Kyrgyz Republic (DRA). DRA officials were described
as a strong barrier to civil society’s ability to influence pol-
icy, insofar as it was suggested that they had resorted to
defamation of MeTA online. It was suggested that previ-
ous civil society recommendations to the ministry of
health may be behind this. Tensions with the ministry of
health were highlighted in Jordan, where civil society rep-
resentatives described facing strong pushback and exclu-
sion, most recently concerning negotiations to drive down
the price of a Multiple Sclerosis treatment by 50%.
According to one civil society representative, sometimes
giving civil society a hearing in consultations was used as
a way to silence them and prevent civil society action:
The fight is mainly with the Ministry of Health. The
ministry make many promises of policy and price
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changes to CSOs… some believe that the minister of
health is stalling and creating delays, cancelling
meetings last minute and making promises which are
not delivered…they don’t just say no as if they did we
could bypass them and go directly to the royal court.
[P2]
Power imbalances
Power imbalances outside of MeTA were described as
greatly influencing which actors had a say in policy
decisions by the majority of respondents. Government
officials were reported to have the strongest voice in
Uganda. In Ghana, the government were reported to
have the most power inside of MeTA, with this
imbalance exacerbated by something of a representa-
tional monopoly within MeTA. Until recently, there
was only one civil society representative inside MeTA,
remedied only after a visit from international
members:
Thankfully, during a visit from international members
from the WHO and HAI it was agreed that one person
was not sufficient to represent all of the civil society
members of MeTA…that proposal sparked resistance
from the leadership but the number of representatives
was increased to two. [P5]
In Kyrgyzstan the main perceived barrier to civil soci-
ety engagement was the DRA’s unchecked power; gener-
ally, the DRA was thought to have more influence than
the ministry of health on policy and were reported to
marginalise the private sector:
[T]hey [the DRA] can do whatever they want and no
one can stop them; if they hate a group or business
they can put a lot of pressure on them… They cannot
talk about this openly or they will be punished: they
just try to use civil society because the regulatory
agency have such huge power and can put huge
pressure on them. [P13]
Conversely, in Peru, Zambia, Ghana and Jordan,
respondents voiced the opinion that the private sector
not only had a stronger voice than civil society outside
of MeTA but was also more powerful than govern-
ments. This manifested in a number of ways, for
example by having the power to appoint or remove
government officials or influence policy by leveraging
their profits and influence: One respondent also
highlighted the unchecked power of procurement
officers, who had the power to procure certain medi-
cines and supplies, influencing buying patterns of
medicines procurement for their own profit.
Gatekeepers and agenda setting
Where civil society positions did not correlate with the
government’s own agenda, ministers’ own policy agendas
were often identified as a strong factor in inhibiting or
enabling civil society participation outside of MeTA. In
most countries, the strength of government depended
on the relative importance of certain issues to ministers.
The active involvement of government officials inside
the MeTA process was widely seen as greatly beneficial
to raise the profile of issues with governments. However,
although having members of government in powerful
positions within MeTA was reported to increase engage-
ment, many respondents expressed ambivalence. Where
government engagement within MeTA was necessary to
influence policy, sporadic engagement from government
officials represented a hurdle to civil society engagement,
as in Ghana and Uganda:
The strength of the ministry of health in Uganda
barrier to things getting done because if they are not at
the table you have to find a way of getting them to the
table; if they are not in meetings…for example, this
meeting, we feel that it makes our jobs harder. [P11]
Concerns about having government representatives in
powerful positions within MeTA were raised by a par-
ticipant, who emphasised possible conflicts of interest
and difficulties in ensuring that some stakeholders do
not have unchecked power:
For example, there might be changes in policy that
work towards the interests of the government or the
private sector. If the government is the leading member
of the MeTA council, how can this be balanced? Who
will balance it? How can you be critical if you need
them to sign off on every policy change? So I think that
would be a difficult position. Where will people go if
they have problems with the government? I don’t know
what the dynamics would be like [sic] there, if that
would be the system. [P2]
In some cases the disproportionate influence of gov-
ernment officials outside of MeTA was reported as influ-
encing which conversations were conducted within
MeTA. Some respondents referred to powerful individ-
uals within MeTA having their own policy agendas and
using their position to influence which positions MeTA
could take.
It makes a difference in what we can say…because
they are the ones who are listened to, they are the ones
who are consulted by government….If there are
agitations of any kind the president of the Ghana
association is the last person who needs to be
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consulted. So he keeps quiet, you bring the draft to
him…he has the final decision…if he does not like a
point he just sends it back. [P5]
Some interviewees emphasised being non-confrontational
and avoiding making demands in order to be heard. Where
power imbalances were reported to be minimal, this simply
took the form of all stakeholders “agreeing to disagree” [P2].
In Kyrgyzstan it was noted that, due to tensions with the
DRA, civil society members are careful to mediate their
interactions with the DRA. Conversely, respondents in
countries where engagement was low reported taking care
when approaching government officials, as they were
thought to have a large amount of power in the policy
process within and outside of MeTA. Their presence not
only influenced the agenda but also how debates were con-
ducted. For example, in Zambia gaps in services can be
highlighted by civil society, but not expressed as being the
result of government shortcomings:
Our approach is not confrontational. When we speak
with government…if all we do is point fingers and
accuse them of things, nothing happens. We have to
engage in more…civil ways. [P8]
Capacity
Interview responses revealed key variations and similar-
ities in the factors viewed as facilitating and inhibiting
civil society participation. Contrary to the existing litera-
ture, capacity was not seen as a barrier to engagement, it
was however frequently referenced and therefore an
overview of respondents’ views of capacity is also
presented.
While room for further civil skills strengthening with
regards to policy was recognised every interviewee stated
that technical capacity to engage in the area of medi-
cines policy as part of MeTA was strong: In all countries,
capacity was thought to be strengthened through the in-
clusion of members with previous technical or policy ex-
perience due to the skills and recognition they brought
to MeTA:
We have the capacity. We have members who are
trained in health and have had advocacy training,
Master’s degrees, we have retired medical and
pharmaceutical officers. All of these things help us to
be taken seriously. [P5]
Representatives from all countries noted that civil soci-
ety engagement had been strengthened through capacity-
building activities run by MeTA. A civil society respondent
from Uganda stated that whereas previously the Ugandan
government had accused civil society of “just being noisy”,
now the government is aware that civil society within
MeTA “use evidence to get the change that we want”. A
similar view was expressed by a civil society representative
from Jordan, where civil society did not previously possess
the technical skills for evidence-based advocacy. Outside
of MeTA, views of civil society capacity were not always
positive. For example, a respondent from Zambia
expressed a belief that members of professional associa-
tions did not necessarily believe that civil society had the
capacity to engage in policy. A civil society respondent re-
ported that heads of hospitals also had doubts about civil
society capacity and perceived civil society as interfering
with their day to day functioning:
Heads of hospitals, they get a certain level of responsibility
and autonomy with their budgets…they have a lot of
freedom in how they spend it. They don’t want anyone
messing up their good life, so they say, “Who are these
people? What do they know about medicines”? [P10]
A number of respondents expressed the opinion that,
while capacity is an important factor in engaging with
policy, it was not the strongest predictor of civil society
success in the multi-stakeholder process; barriers were
most often perceived in getting powerful stakeholders to
engage once a certain level of capacity had been
achieved:
It doesn't matter how high our capacity is. At the end
of the day, if we cannot engage with government in a
way they appreciate it just doesn’t work. [P15]
Discussion
This research explored the opinions and perceptions of
civil society organisations in the MeTA multi-stockholder
dialogue process. Furthermore, the study used MeTA as a
case study to confirm the factors which limit civil society
engagement in multi-stakeholder dialogue. These findings
advance our understanding of multi-stakeholder dialogue
within the medicines policy arena and provide further in-
sights into how we can effectively foster transparent and
open information sharing to create improved policy
surrounding access to medicines. The study used in-depth
interviews to explore three key themes relevant to the
variations seen in CSO engagement within MeTA; (1)
local political environment (2) power imbalances and (3)
agenda setting/gatekeepers. The study also allowed for the
emergence of new themes in order to gain a deeper under-
standing and identify where improvements might be
made.
Prior research has shown that a lack of civil society cap-
acity can seriously impact civil society's ability to engage
with policy [16]. However, capacity-building strengthening
activities carried out by MeTA did not have any effect on
engagement [15]. Despite stating that they had good
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technical capacity, many civil society representatives did
not perceive themselves as well-positioned to influence
policy. Capacity was not identified as a current barrier to
civil society engagement by any respondent in this study.
This was the case not only in countries where civil society
engagement is strong, but also in those countries where
engagement was reported to be comparatively weak in a
recent MeTA annual review [15].
Of the three main themes explored, political environ-
ment was deemed especially important, and the ultimate
deciding factor for effective collaboration. In countries
where government’s commitment to policy change in the
area of access to medicines is strong, civil society find dia-
logue and collaboration more consistent and productive
than CSOs do in those countries where commitment and
multi-stakeholder engagement is weak. In addition, where
governments offer an open consultation process to civil
society, engagement is higher than in political systems in
which governments regularly block policy consultations or
changes proposed by civil society.
Unequal power dynamics and relative stakeholder
strength outside of MeTA were seen to hamper civil
society engagement on a number of levels. Firstly, where
the private sector has more influence than civil society
due to a higher degree of political currency in consulta-
tions or the ability to leverage monetary resources, civil
society are disadvantaged. The powerful position of other
stakeholders such as procurement officers, hospital heads
and government officials were also cited as an issue. Ul-
timately, wherever political will was lacking or the private
sector had a disproportionate influence on the direction of
policy, civil society are disadvantaged. Power imbalances
strongly influence the extent of ownership felt by actors
over issues or solutions which emerge within MeTA.
Actors have varying levels of power within MeTA and
power imbalances were evident, particularly where civil
society were underrepresented or only involved in con-
sultative processes. Issue networks themselves do not have
policy goals; these arise from actors within the network
and some actors have more power than others in the issue
formation process. Furthermore, if issue definition in-
volves demonstrating that a party is responsible for a cer-
tain situation and proposing credible solutions, a culture
of having to be careful in ‘blaming’ government officials
for previous mistakes may stand in the way of truly par-
ticipatory engagement for civil society [18].
The issue of gatekeepers and agenda setting as a barrier
to policy engagement was most commonly raised regard-
ing government officials and the position they hold within
MeTA. Indeed, it is suggested that in countries with a less
hospitable political environment to civil society, issue
adoption often occurs when the issue is championed by
one major player in the broader network [17]. Gatekeepers
are seated in powerful positions within MeTA due to their
power to lend credibility, sources or pathways to a raised
‘issue’. These benefits were widely discussed and seen as
integral to MeTA’s policy influencing activities. However,
gatekeepers can also block the entry of policy issues into
the policy process; gatekeepers have “powerful demonstra-
tion effects, signalling that certain causes are important”
[19]. If gatekeepers disagree with civil society positions,
this represents a significant disadvantage for civil society,
insofar as their views may be silenced [23]. Here, it is
likely that the policy suggestions most likely to reach pol-
icy makers are those most well-aligned to the positions
already held by the policy maker or the wider government
department. Conversely, the position of civil society is at
its strongest within MeTA when the process of issue for-
mation was closest to the principle of collaborative
governance [24, 25]. That is, where stakeholders repre-
senting different interests make policy decisions or recom-
mendations to a final decision-maker who does not
substantially change consensus recommendations.
There is a sophisticated academic debate on the ‘demo-
cratic deficit’ in global policy-making and the approaches
necessary to make public policy-making more accountable
[26]. Despite this, issues of accountability were rarely, if
ever, explicitly discussed during the interviews. It is argued
that multi-sectoral networks should be embedded in a
pluralistic system of accountability, making use of a
combination of accountability, as outlined by Benner and
colleagues [27]. For example, they may employ measures
of “internal accountability” (oversight committees) or
“reputational accountability” (naming and shaming) [27]. It
is likely that more rigorous and systematic accountability
mechanisms are needed within MeTA in order to maintain
the legitimacy of decision-making processes. Overall, fur-
ther research into the power structure of local MeTA
councils and meetings would be useful in order to identify
the conditions under which stakeholders act collaboratively.
This study suggests that, particularly where government of-
ficials are serving as chairs, clear guidelines to government
engagement within MeTA should be formulated in order to
ensure that proper checks and balances are put in place.
This would represent a step towards ensuring that no one
actor has the power to sign off on policy changes within
MeTA. It is unclear whether any government officials in-
volved with MeTA have been systematically trained in civil
society relations but, although actors would still be
confined by the overarching political environment, such
training may prove useful in ensuring that there is enough
space for diversity of opinion and debate both within and
outside of MeTA. Furthermore, clearly defined goals and
specific expected outputs should be designed by each
MeTA country group in order to focus and motivate MeTA
members and ensure accountability. In this way, actors may
be more open to the strategies of other sectors if these
strategies appear useful for achieving agreed upon goals. It
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may be useful to complement this with some frank discus-
sion about perceptions of power relations within and out-
side of MeTA, the various sources of influence around the
table and the strategies needed to address any problematic
power differentials. This may involve the use of professional
facilitation or introduction of specific measures to “level the
playing field” through, for example, formalised power-
sharing rules, or increased representation of “weaker” stake-
holder groups.
The qualitative nature of the study means that this
research draws heavily on the personal experiences of civil
society members. While this is an advantage insofar as we
have gained an in-depth understanding of their perceptions
of the multi-stakeholder process, a reliance on personal re-
flections limits this paper’s reach to some extent by relying
on respondents’ ability to recall events or actions. The pos-
sibility of participants wanting to shine a favourable light
on the work of their own organisations should also be
considered, as should wishes not to offend country govern-
ments by portraying them as unresponsive. Furthermore,
the use of convenience sampling in selection of study par-
ticipants may lead to bias due to the fact any civil society
members attending the conference in Geneva may possibly
be more engaged in the policy process than other civil
society counterparts.
In reality, actors in a network may come together be-
cause of disagreements over the presence of a solution
to certain issues. The practice of collaboration has long
demonstrated that multi-stakeholder partnerships and
relationships are often fraught, with many facing signifi-
cant setbacks in delivering the resources or outcomes
originally stated. Even where preliminary milestones
have been achieved, multi-stakeholder groups often still
experience collaborative inertia which can have signifi-
cant effects on outputs [27]. In light of these challenges,
MeTA serves as an interesting case study to explore how
civil society are encouraged or prevented from voicing
opinions and influencing policy in a meaningful way
without assuming shared agendas.
Conclusion
This study enriches the current understanding of civil
society engagement in multi-stakeholder dialogue, by pro-
viding ginsights into the opinions and perceptions of CSO’s
participating in a multi-stakeholder alliance, MeTA, aimed
at improving access to medicines policy. The studies con-
firms that the political environment, relative stakeholder
strength and gatekeepers have a significant role in CSO en-
gagement within the MeTA issue network. However, it was
largely seen that the political environment was the one fac-
tor that enabled or disabled all others. In this case, the
findings counter the argument that CSO barriers to en-
gagement are predominantly due to capacity issues. It is
evident that there is no one-size-fits-all template for civil
society engagement: any interventions in these relation-
ships must be tailored to their specific contexts and goals.
However, for MeTA it is likely that the use of more rigor-
ous and systematic accountability mechanisms in order to
maintain the legitimacy of decision-making processes and
establish more equal power relations would significantly
benefit the engagement of CSOs. This study provides a
significant starting point for a discussion about potential
barriers and solutions for improving transparency,
accountability and evidenced-based policy making in im-
proving access to medicines through multi-stakeholder
dialogue.
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